Hikma Appoints Global Head of Intellectual Property and US General Counsel

Eatontown, NJ, October 4, 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) today announced the appointment of Samuel (Sam) Park as Global Head of Intellectual Property (IP) and General Counsel for the US, effective immediately.

Press Release Corporate 4 October 2018

Mr. Park joins Hikma from Winston & Strawn LLP where he advised leading pharmaceutical companies on a variety of legal and intellectual property issues, from determining the appropriate IP strategies to litigating patent-protected pharmaceutical products. Mr Park will be based in the US.


Commenting on the appointment, Hussein Arkhagha, Hikma’s global General Counsel, said, “We are very excited that Sam has joined Hikma. He brings a wealth of legal experience and has an impressive record of challenging patents.  Sam will play a pivotal role in enhancing our R&D program, enabling us to bring more differentiated products to the market.”


Commenting on his appointment, Mr. Park said, “Hikma has a strong legacy and has been investing in its people and capabilities to prepare for its next phase of growth. I share the company’s enthusiasm for the future and look forward to helping Hikma achieve its ambitions.”


Mr. Parks holds a B.A. in Biological Sciences from the University of Chicago and a J.D., magna cum laude, from Loyola University School of Law. He is licensed to practice in Illinois, New Jersey, New York, and the United States Patent & Trademark Office.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.